Product Images Atorvastatin Calcium

This is a medication label for Atorvastatin Calcium, a drug used to lower cholesterol levels in the blood. The label provides instructions on how to take the medication, including dosage and frequency. It also includes important information such as the lot number, expiration date, and distributor name. Users should keep the container tightly closed and out of reach of children. This medication should only be taken with a prescription from a healthcare provider.*

useful description cannot be generated as there is missing information in the text. The dosage frequency and the number of tablets to be taken are left blank.*

This is a medication label for Atorvastatin Calcium. The dosage instructions are partially filled and it indicates that the tablets are to be stored at room temperature. It also provides the NDC, lot number, and expiration date of the medication. The medication is distributed by QPharma, Inc. and it is only available through prescription.*

This text appears to be a statistical analysis report comparing the effect of Atorvastatin (a drug used to lower cholesterol levels) versus a placebo. The report presents the cumulative incidence in percentage for different age brackets (40+) and shows that Atorvastatin has a lower incidence rate compared to the placebo. The study was conducted for 3.5 years and the statistical significance of the results is indicated by the p-value (p=0.0005).*

The text represents a graph or chart showing the Cumulative Hazard (%) and Time to First Primary Endpoint Through Four (4) Years of Follow-up (Years). The hazard percentage increases with time, and the graph shows that after four years, the hazard will be significantly higher. The HR is 0.63, and the p-value is 0.001. This information appears to be from a medical study or clinical trial.*

This is a statistical report on the effectiveness of two different doses of Atorvastatin medication on major cardiovascular events. The table shows the percentage of subjects who experienced the event, and the HR (Hazard Ratio) and p-value for each dose. The higher dose (80mg) had a lower percentage of subjects experiencing the event, with a statistically significant HR of 0.78 (meaning a lower risk) compared to the lower dose (10mg). The graph shows the time to the first major cardiovascular endpoint over four years.*